Premium
Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients
Author(s) -
Ditschkowski M,
Elmaagacli AH,
Trenschel R,
Steckel NK,
Koldehoff M,
Beelen DW
Publication year - 2006
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2005.00453.x
Subject(s) - medicine , hematopoietic stem cell transplantation , transplantation , disease , stem cell , stage (stratigraphy) , haematopoiesis , graft versus host disease , hematopoietic cell , surgery , gastroenterology , oncology , paleontology , genetics , biology
This study aimed to evaluate the outcome following myeloablative allogeneic hematopoietic stem cell transplantation (SCT) among patients older than 50 yr of age. A total of 215 patients with a median age of 57 yr underwent allogeneic hematopoietic SCT for early (41%) or advanced (59%) hematologic malignancies. After a median follow‐up of 36 months a 10‐yr survival estimate of 56 ± 6% could be assessed for patients in early disease stages while patients with advanced diseases showed a significantly decreased survival probability of 31 ± 5% (p < 0.0002). Transplant related mortality (TRM) at day 100 and 365 post‐transplant was 13% and 30% for early but increased to 21% and 49% for advanced disease stages. As major determinants of TRM advanced disease stage (p < 0.0001) and occurrence of grades II–IV graft‐vs.‐host disease (GVHD) (p < 0.0001) were identified. These results show that hematopoietic SCT following myeloablative conditioning is also applicable to elderly patients whereas disease stage and high‐grade GVHD represent the essential prognostic factors for outcome.